CEND-1 + FOLFIRINOX for Digestive Cancer
(CENDIFOX Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot use any other anti-cancer therapy while participating. It's best to discuss your current medications with the trial team.
What data supports the effectiveness of the treatment CEND-1 + FOLFIRINOX for digestive cancer?
Research shows that FOLFIRINOX, a part of the treatment, has been effective in improving survival and quality of life in patients with pancreatic cancer compared to other treatments. It has shown better progression-free survival and overall survival in patients with borderline resectable pancreatic cancer compared to a gemcitabine-based regimen.12345
Is the combination of CEND-1 and FOLFIRINOX safe for humans?
What makes the CEND-1 + FOLFIRINOX treatment unique for digestive cancer?
The CEND-1 + FOLFIRINOX treatment is unique because it combines CEND-1, a novel agent, with FOLFIRINOX, a chemotherapy regimen known for its effectiveness in pancreatic cancer. This combination aims to enhance the delivery and effectiveness of chemotherapy, potentially offering a new approach for treating digestive cancers.12358
What is the purpose of this trial?
This is a phase IB/IIA trial to ensure the safety of Certepetide (LSTA1/CEND-1) in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers
Research Team
Anup Kasi, MD
Principal Investigator
University of Kansas Medical Center
Eligibility Criteria
This trial is for adults with certain types of cancer (pancreatic, colon, or appendiceal) who are in good physical condition and have not had other cancer treatments in the past 2 years. They must be able to understand the study and agree to its terms. Pregnant women and those with serious heart conditions or infections are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Folfirinox with or without Panitumumab and CEND-1 for 3 cycles, followed by surgery
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for overall survival and disease-free survival
Treatment Details
Interventions
- CEND-1
- Folfirinox
- Panitumumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Anup Kasi
Lead Sponsor
Cend Therapeutics Inc.
Collaborator